A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer

NCT04247984 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

264

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

BIOLOGICAL: Bevacizumab
DRUG: Capecitabine
DRUG: Irinotecan
DRUG: 5-FU
DRUG: CF
DRUG: Irinotecan

Sponsor

Chinese Academy of Medical Sciences

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]